Bantam Pharmaceutical, a New York, US-based pharmaceutical company specialising in the discovery and development of compounds to treat cancer with a focus on RNA translation, has appointed Michael Luther as President and Chief Executive.
Before joining Bantam, Luther was Senior Vice President and General Manager for the Discovery and Development Services Division of Albany Molecular Research. He has more than 25 years' experience as the leader of various drug discovery and development programmes and operations for biopharmaceutical firms including GSK and Merck, where he led the advancement of multiple programmes to the clinic and approval.
